Can Cardinal Health Stock Repeat Its Last Five Years?

Cardinal Health (CAH) stock rose 454.6% from September 2021 to November 2026, with sales growth of 54% to $258 billion. The stock's rise was largely driven by an increase in its price-to-earnings multiple, which rose from 12.6 to 35.2, and a 19.4% reduction in share count due to buybacks. The company's net margin remained relatively stable.

Original reporting
Published Nov 10, 2026, 1:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 1:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Can Cardinal Health Stock Repeat Its Last Five Years? — source image
Decision brief

The 30-second read

$CAHNeutralLow
01

Why it matters

The article provides a historical performance review without new data, offering limited actionable insight for traders.

02

Market read

Low relevance; the piece is a retrospective analysis with no fresh catalyst.

03

What to watch

Potential impact of payer reforms, competitive pressure from other distributors, and macro‑economic headwinds are not addressed.

Relevance 4/10Novelty 2/10Timing: none

Background

Cardinal Health is a major drug distributor; its stock has risen dramatically since 2021, driven largely by valuation expansion and share repurchases.

Company-level read

Ticker impact

$CAHNeutralHigh confidence
Context

The article retrospectively analyzes Cardinal Health's 454.6% stock rise over five years and attributes it to multiples, buybacks and sales growth, without presenting new information or a fresh catalyst.

Expected impact

no immediate impact

Evidence & confidence

The piece recaps past performance and does not disclose any new event that would move the stock price.

Market effects

None; the analysis does not affect the broader healthcare distribution sector.

None; no regional market effect is discussed.

None; the article is a company‑specific retrospective.

Counterpoint

The stock's past surge may be unsustainable; future performance could be limited by margin compression and valuation constraints.

Key entities

  • Cardinal Health

    U.S. drug distributor (ticker CAH).

Related articles

$CAHHighAI 8/10

Argus raises Cardinal Health stock price target on strong earnings

Argus raised its price target for Cardinal Health (CAH) to $309 from $264, citing strong Q1 2027 results. The company reported 5% revenue growth and 28% adjusted EPS growth to $3.26, exceeding estimates. Cardinal Health also raised its fiscal 2027 adjusted EPS guidance to $12.80-$13.00. The stock is near its 52-week high, up 53% in six months, and is considered undervalued by InvestingPro.

$CAHHighAI 8/10

Cardinal Health Q1 Earnings Call Highlights

Cardinal Health (CAH) raised its full-year pharmaceutical segment profit growth forecast to 10-12% and maintained revenue growth outlook of 3-5%. CEO Jason Hollar highlighted contract renewals, including a long-term agreement with CVS Health. Medical unit revenue was flat at $3.2B, but profit exceeded expectations. The company raised its annual revenue and profit growth forecasts for its 'other' category, citing strong demand.

$CAHHighAI 8/10

Cardinal Health Raises Fiscal 2027 Growth Targets for Two Segments

Cardinal Health raised its fiscal 2027 earnings forecast after Q1 non-GAAP EPS rose 28% to $3.26. Revenue increased 5% to $67.513 billion. Pharmaceutical and Specialty Solutions revenue grew 6%, while Global Medical Products and Distribution revenue was flat. The company also completed $500 million in share repurchases.

$CAHHighAI 8/10

Cardinal Health Inc (CAH) (Q1 2027) Earnings Call Highlights: Record $1 Billion

Cardinal Health (CAH) reported Q1 2027 earnings with record operating income of $1 billion. GMPD segment revenue was flat at $3.2B, with full-year profit expected toward the low end of $200-$220M due to high petroleum costs. Pharmaceutical revenue growth faced headwinds from IRA WAC reductions, partially offset by GLP-1 growth. Earnings growth is expected to moderate in Q2 and Q3 before strengthening in Q4. The company raised its fiscal 2027 EPS guidance to $12.80-$13.00, up from $12.40-$12.60.

$CAHHighAI 8/10

Cardinal Health (CAH) Q1 2027 Earnings Call Transcript

Cardinal Health (CAH) reported Q1 2027 revenue of $67.5B (+5% YoY) and raised fiscal 2027 EPS guidance to $12.80-$13.00. The company renewed its contract with CVS Health (CVS) through 2032, securing long-term stability. Pharma segment revenue grew 6%, while GMPD revenue was flat. Profit increased across all segments, with operating income reaching $1B. The company repurchased $500M in shares and maintained strong cash flow.